2- chloro- N- (2- (5- (dimethylamino)naphthalene- 1- sulfonamido)ethyl)- 4- (2- (1- hydroxy- 3- methylbutan- 2- ylamino)- 9- isopropyl- 9H- purin- 6- ylamino)benzamide

an antineoplastic agent; structure in first source

Also Known As:

VMY-1-103

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        2-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamide: 4
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Dansyl Compounds
        2-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamide: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Dansyl Compounds
      - 2-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamide: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Dansyl Compounds
      - 2-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamide: 4

Experts

1.	Albanese, Chris: 4 articles (11/2014 - 08/2010)
2.	Ringer, Lymor: 4 articles (11/2014 - 08/2010)
3.	Sirajuddin, Paul: 4 articles (11/2014 - 08/2010)
4.	Rodriguez, Olga: 3 articles (11/2014 - 08/2010)
5.	Schlegel, Richard: 3 articles (11/2014 - 11/2011)
6.	Avantaggiati, Maria Laura: 2 articles (11/2014 - 08/2010)
7.	Heckler, Mary: 2 articles (11/2014 - 11/2011)
8.	Sivakumar, Angiela: 2 articles (11/2014 - 10/2012)
9.	Yenugonda, Venkata: 2 articles (11/2014 - 10/2012)
10.	Lisanti, Michael P: 2 articles (10/2012 - 08/2010)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 08/15/2010 - "Our results demonstrate that VMY-1-103 was more effective in inducing apoptosis in PCa cells than its parent compound, purvalanol B, and support the testing of VMY-1-103 as a potential small molecule inhibitor of prostate cancer in vivo." 08/15/2010 - "In the present study, we tested the efficacy of VMY-1-103 in inhibiting HRG-induced cell proliferation in LNCaP prostate cancer cells. " 08/15/2010 - "VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells."
2.	Medulloblastoma 11/01/2011 - "In the current study, we have identified new mechanisms of action by which VMY-1-103 affected cellular proliferation in medulloblastoma cells. " 11/01/2011 - "Our data suggest that VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma." 11/01/2011 - "VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells." 10/15/2012 - "More importantly, in vivo MRI and single voxel proton MR-Spectroscopy further established that VMY-1-103 inhibited disease progression and affected key metabolites in a mouse model of hedgehog-driven medulloblastoma."
3.	Neoplasms (Cancer) 10/15/2012 - "We developed a rapid organic phase extraction technique and validated wide and functional VMY-1-103 distribution in various mouse tissues, consistent with its enhanced potency previously observed in a variety of human cancer cell lines. " 11/15/2014 - "VMY-1-103 (VMY), a dansylated analog of purvalanol B, displays rapid and potent anti-tumor activities, however the pathways by which VMY works are not fully defined. "
4.	Breast Neoplasms (Breast Cancer) 11/01/2011 - "VMY-1-103, a novel dansylated analog of purvalanol B, was previously shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. " 08/15/2010 - "We have recently designed and synthesized a novel dansylated analog of purvalanol B, termed VMY-1-103, that inhibited cell cycle progression in breast cancer cell lines more effectively than did purvalanol B and allowed for uptake analyses by fluorescence microscopy. "
5.	Disease Progression 10/15/2012 - "More importantly, in vivo MRI and single voxel proton MR-Spectroscopy further established that VMY-1-103 inhibited disease progression and affected key metabolites in a mouse model of hedgehog-driven medulloblastoma."

Related Drugs and Biologics

1.	histidine-rich proteins
2.	purvalanol B
3.	Protons (Proton)